| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

7 February 2022

ORYZON reports results and corporate update for Q4 and year ended December 31, 2021

11 January 2022

ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities

4 January 2022

ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder

10-13 January 2022

H.C. Wainwright Bioconnect Conference

10-12 January 2022

Biotech Showcase 2022

10-13 January 2022

40th Annual J.P. Morgan Healthcare Conference

5-7 January 2022

11th Annual LifeSci Partners Corporate Access Event 2022

3 January 2022

ORYZON to hold multiple corporate activities in January

13 December 2021

ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

22 November 2021

ORYZON announces new Global Chief Business Officer and expansion of US corporate activities

Pagination

First page «
Previous page ‹
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel